| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the1Ocular Oncology Service and 2Ophthalmic Pathology Laboratory, Department of Ophthalmology, Helsinki University Central Hospital, Helsinki, Finland.
PURPOSE. To investigate the very long-term prognosis of patients with uveal melanoma and the clinical characteristics influencing it.
METHODS. Charts, registry data, and histopathologic specimens of 289 consecutive patients with choroidal and ciliary body melanoma treated in the district of the Helsinki University Central Hospital, Finland, between 1962 and 1981 were audited. Definitions for coding the cause of death were adapted from the Collaborative Ocular Melanoma Study (COMS). Competing risks were taken into account by using cumulative incidence analysis and competing risks regression.
RESULTS. Of the 289 patients treated, 239 were deceased at the end of follow-up. The audited cause of death was uveal melanoma in 145 (61%) of them. The median follow-up of the 50 survivors was 28 years. The original histopathologic diagnosis of metastasis and second cancer was correct in 91% of all specimens, but immunohistochemical reassessment changed 10% of biopsy and 7% of autopsy diagnoses. Of 45 positive autopsies, 18% were performed without suspicion of melanoma. Uveal melanoma–related mortality was 31% (95% confidence interval [CI], 26–37) by 5 years, 45% (95% CI, 40–51) by 15 years, 49% (95% CI, 43–55) by 25 years, and 52% (95% CI, 45–58) by 35 years, according to cumulative incidence analysis. Of patients who died of uveal melanoma, 62%, 90%, 98%, and 100% did so within 5, 15, 25, and 35 years, respectively. Between 15 and 35 years, 20% to 33% of deaths were still due to uveal melanoma. By competing risks regression analysis, the hazard ratio was 1.08 (P = 0.0012) for each millimeter increase in tumor diameter, 2.27 (P = 0.0076) for extraocular growth, and 1.89 (P = 0.0011) for ciliary body involvement.
CONCLUSIONS. Metastatic uveal melanoma was the leading single cause of death throughout the study. Cumulative incidences provide a sound basis for patient counseling and design of trials.
This article has been cited by other articles:
|
|
 |
|
  A. Ulmer, J. Beutel, D. Susskind, R.-D. Hilgers, F. Ziemssen, M. Luke, M. Rocken, M. Rohrbach, G. Fierlbeck, K.-U. Bartz-Schmidt, et al. Visualization of Circulating Melanoma Cells in Peripheral Blood of Patients with Primary Uveal Melanoma Clin. Cancer Res., July 15, 2008; 14(14): 4469 - 4474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Buijs, J. A. Vossen, K. Hong, C. S. Georgiades, J.-F. H. Geschwind, and I. R. Kamel Chemoembolization of Hepatic Metastases from Ocular Melanoma: Assessment of Response with Contrast-Enhanced and Diffusion-Weighted MRI Am. J. Roentgenol., July 1, 2008; 191(1): 285 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kivela and E. Kujala Preenucleation Radiotherapy, Uveal Melanoma, and Competing Risks Arch Ophthalmol, April 1, 2008; 126(4): 580 - 581. [Full Text] [PDF]
|
|
|
|
|
|
T. Tsai and J. M. O'Brien The Future Promise and the Current Reality of Genetic Prognostication in Patients With Uveal Melanoma Arch Ophthalmol, March 1, 2008; 126(3): 413 - 415. [Full Text] [PDF]
|
|
|
|
 |
|
 A. D Singh, K. Sisley, Y. Xu, J. Li, P. Faber, S. J Plummer, H. S Mudhar, I. G Rennie, P. M Kessler, G. Casey, et al. Reduced expression of autotaxin predicts survival in uveal melanoma Br. J. Ophthalmol., October 1, 2007; 91(10): 1385 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Folberg, L. Leach, K. Valyi-Nagy, A. Y. Lin, M. A. Apushkin, Z. Ai, V. Barak, D. Majumdar, J. Pe'er, and A. J. Maniotis Modeling the Behavior of Uveal Melanoma in the Liver Invest. Ophthalmol. Vis. Sci., July 1, 2007; 48(7): 2967 - 2974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Bosch, J. A. Thompson, M. K. Srivastava, U. K. Iheagwara, T. G. Murray, M. Lotem, B. R. Ksander, and S. Ostrand-Rosenberg MHC Class II-Transduced Tumor Cells Originating in the Immune-Privileged Eye Prime and Boost CD4+ T Lymphocytes that Cross-react with Primary and Metastatic Uveal Melanoma Cells Cancer Res., May 1, 2007; 67(9): 4499 - 4506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Folberg, Z. Arbieva, J. Moses, A. Hayee, T. Sandal, S. Kadkol, A. Y. Lin, K. Valyi-Nagy, S. Setty, L. Leach, et al. Tumor Cell Plasticity in Uveal Melanoma: Microenvironment Directed Dampening of the Invasive and Metastatic Genotype and Phenotype Accompanies the Generation of Vasculogenic Mimicry Patterns Am. J. Pathol., October 1, 2006; 169(4): 1376 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lindegaard, P. Isager, J. U. Prause, and S. Heegaard Optic nerve invasion of uveal melanoma: clinical characteristics and metastatic pattern. Invest. Ophthalmol. Vis. Sci., August 1, 2006; 47(8): 3268 - 3275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. McKenna and J. A. Kapp Accumulation of Immunosuppressive CD11b+ Myeloid Cells Correlates with the Failure to Prevent Tumor Growth in the Anterior Chamber of the Eye J. Immunol., August 1, 2006; 177(3): 1599 - 1608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Collaborative Ocular Melanoma Study Group* Development of Metastatic Disease After Enrollment in the COMS Trials for Treatment of Choroidal Melanoma: Collaborative Ocular Melanoma Study Group Report No. 26 Arch Ophthalmol, December 1, 2005; 123(12): 1639 - 1643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R van Ginderdeuren, E van Limbergen, and W Spileers 18 Years' experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma Br. J. Ophthalmol., October 1, 2005; 89(10): 1306 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A D Singh, I G Rennie, T Kivela, S Seregard, and H Grossniklaus The Zimmerman-McLean-Foster hypothesis: 25 years later Br. J. Ophthalmol., July 1, 2004; 88(7): 962 - 967. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
